Bessemer Group’s CytomX Therapeutics CTMX Stock Holding History

Bessemer Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-80,000	Closed	-$666K	–	1418
2020 Q2	$666K	Buy	+80,000	New	+$743K	﹤0.01%	902

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bessemer Group's CTMX Position: Q3 2020 in Review

Bessemer Group sold out of CytomX Therapeutics (CTMX) in Q3 2020, closing a stake of 80,000 shares — an estimated $666K sold.

Bessemer Group first reported a position in CTMX in Q2 2020 and held it in 1 quarter. The position peaked at $666K in Q2 2020. 130 funds tracked by Wall St. Rank hold CTMX as of Q3 2020.

Bessemer Group reported no remaining CytomX Therapeutics position as of Q3 2020 after selling out during the quarter.
Bessemer Group sold 80,000 CytomX Therapeutics shares in Q3 2020, an estimated $666K.
Bessemer Group first reported a position in CytomX Therapeutics in Q2 2020 and held it in 1 quarter.
Bessemer Group's CytomX Therapeutics position peaked at $666K in Q2 2020.
130 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.